AtaiBeckley acquired by Eli Lilly and Company
Eli Lilly and Company acquired AtaiBeckley, a drug development brand.
Transaction summary
- Target
- AtaiBeckley
- Acquirer
- Eli Lilly and Company
- Seller
- -
- Announced
- -
- Geography
- -
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-10-08
- Latest update
- 2026-10-18
Value and multiples
100% enterprise value
USD 2.8B
100% enterprise value | USD
Basis: Estimated
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- Estimated enterprise value: USD 2.8bn.
Source summary
Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
ConfirmedAcquisition of AtaiBeckley by Eli Lilly and Company.
Open sourceContinue your research
Related transaction comps
Biotech
Edgewise Therapeutics' Muscular Dystrophy Business acquired by Servier
2026-07-13 · Confirmed
View transaction → BiotechTubulis acquired by Gilead Sciences
2026-05-21 · Confirmed
View transaction → BiotechAimmune Therapeutics acquired by Sociétés des Produits Nestlé S.A. / Nestlé Health Science
2020-08-31 · Estimated
View transaction → BiotechITM Isotope Technologies Munich SE acquired by Telix Pharmaceuticals Limited
- · Confirmed
View transaction →